Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises PT to $163.

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises PT to $163.

Morgan Stanley has maintained its overweight rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), while raising the firm's price target to $163 from $140. The investment bank's decision comes amidst positive feedback from key opinion leaders regarding Jazz Pharmaceuticals' Modeyso, a therapy for an ultra-rare brain tumor. According to the research note, the approval of Modeyso has received positive feedback from key opinion leaders, which has bolstered the firm's confidence in the potential of the confirmatory Phase 3 study [1].

Jazz Pharmaceuticals develops medicines for serious diseases, with a portfolio that includes Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos. These products treat conditions such as excess daytime sleepiness in narcolepsy patients, tepatic veno-occlusive disease (VOD), and other ailments. While the lead US indication for Modeyso in the recurrent setting is niche, the positive feedback from key opinion leaders has increased the firm's assurance about the potential of the confirmatory ACTION trial, which could boost peak US sales to over $400 million [1].

The firm's strong pipeline and recent approvals have positioned Jazz Pharmaceuticals as a promising stock for investors. However, the investment bank acknowledges that certain AI stocks may offer greater upside potential with less downside risk. Investors should consider these factors when evaluating their portfolios.

References:
[1] https://finance.yahoo.com/news/bofa-raises-pt-jazz-pharmaceuticals-035706393.html